FDA — authorised 16 April 2021
- Application: BLA761111
- Marketing authorisation holder: HOSPIRA INC
- Indication: Labeling
- Status: approved
🇺🇸 Neulasta in United States
FDA authorised Neulasta on 16 April 2021
Marketing authorisation
Neulasta in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Hematology approved in United States
Frequently asked questions
Is Neulasta approved in United States?
Yes. FDA authorised it on 16 April 2021.
Who is the marketing authorisation holder for Neulasta in United States?
HOSPIRA INC holds the US marketing authorisation.